SCHEDULE: RTW Investments Discloses Stake in CG Oncology

RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 8.3% in CG Oncology, Inc., holding 6,984,808 shares.

Summary

• RTW Investments, LP, an investment adviser, and Roderick Wong, its Managing Partner and Chief Investment Officer, have jointly filed a Schedule 13G.
• This filing indicates their beneficial ownership of 6,984,808 shares of CG Oncology, Inc. Common Stock.
• This holding represents approximately 8.3% of the class of securities outstanding as of February 25, 2026.
• The shares are held by investment funds managed by RTW Investments, LP.
• The filing asserts that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a known investment firm, but provides no operational or financial performance data for CG Oncology, Inc.

Positives

• RTW Investments, LP, a significant investment entity, has taken a notable stake in CG Oncology, Inc., potentially signaling confidence in the company's prospects.
• The ownership stake of 8.3% is substantial and could indicate a strategic investment.

Negatives

• The filing does not contain any negative financial results or operational issues; it is purely a disclosure of beneficial ownership.

Risks

• As an investment adviser, RTW Investments, LP's investment strategy may involve active trading, which could lead to future changes in ownership levels.
• The filing does not detail specific risks related to CG Oncology, Inc.'s business operations, but general market and company-specific risks inherent in the biotechnology sector apply.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from CG Oncology, Inc. However, the investment by RTW Investments, LP may imply a positive outlook from the investor's perspective.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake acquisitions by institutional investors like RTW Investments, LP in biotechnology companies, particularly those focused on oncology, are common as these firms seek to capitalize on potential breakthroughs and market growth. This filing indicates a substantial interest in CG Oncology, Inc. within the competitive biotech landscape.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by RTW Investments, LP may be viewed positively by existing shareholders, potentially indicating increased institutional interest and confidence in the company.
• Management: The filing confirms a substantial investor's interest, which could influence strategic discussions and board composition over time.
• Potential Investors: This disclosure may attract further attention from other investors interested in CG Oncology, Inc.

Next Steps

• RTW Investments, LP and Roderick Wong will file amendments to this statement if any material changes occur in their beneficial ownership.
• CG Oncology, Inc. will continue its business operations, with potential future disclosures regarding its financial performance and strategic developments.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide performance data or strategic updates for CG Oncology, Inc. While the significant stake by RTW Investments, LP is noteworthy, it does not offer sufficient information to make a buy or sell decision. Therefore, a 'hold' recommendation is appropriate pending further operational and financial disclosures from the company.

Keywords

CG Oncology, RTW Investments, Schedule 13G, Beneficial Ownership, Roderick Wong, Investment Adviser, Biotechnology, SEC Filing, Common Stock